Skip to main navigation
Ventyx Biosciences, Inc. Ventyx Biosciences, Inc.
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Advisory Board
    • Contact
  • Science
  • Pipeline
    • Overview
    • VTX958
    • VTX002
    • VTX2735
    • VTX3232
  • Investors
    • Overview
    • News & events
    • Stock information
    • Governance
    • Financials & filings
    • IR resources
  • Careers
  • News Releases
  • Events
  • Presentations

News Releases

News Releases

January 26, 2023
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
Read more
January 12, 2023
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
Read more
January 5, 2023
Ventyx Biosciences to Host R&D Event on January 26, 2023
Read more
December 1, 2022
Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis
Read more
November 22, 2022
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Read more
November 3, 2022
Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Read more
October 27, 2022
Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022
Read more
October 27, 2022
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Read more
September 19, 2022
Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock
Read more
August 29, 2022
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Read more
  • Current page 1
  • Page 2
  • Page 3
  • Next page ›
  • Last page »
Displaying 1 - 10 of 26


Email Alerts


FAQ


Contact IR


RSS Feeds
Contact us
info@ventyxbio.com
  • Privacy Policy
  • Terms Of Use
© 2023 Ventyx Biosciences, Inc. All rights reserved.
linkedin
Ventyx Biosciences, Inc.